Umeclidinium bromide/vilanterol

Umeclidinium bromide/vilanterol (trade name Anoro Ellipta) is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is applied as an inhalation.

Umeclidinium bromide/vilanterol
Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesAnoro Ellipta
AHFS/Drugs.comanoro-ellipta
License data
Pregnancy
category
  • US: C (Risk not ruled out)
    Routes of
    administration
    Inhalation (DPI)
    ATC code
    Legal status
    Legal status
    Identifiers
    KEGG

    References

    1. Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
    2. "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.